Therapies and Protocols Library
Every article, presentation, spotlight, and news item we've tagged to Therapies and Protocols.
Showing 1–24 of 79
Restore Hyper Wellness kicks off NAD Month to educate on IV, IM therapies
Restore Hyper Wellness is promoting NAD supplementation through IV and intramuscular delivery formats, capitalizing on significant year-over-year increases in consumer search interest for NAD-related therapies. The initiative positions NAD precursors and direct NAD administration as tools for cellular energy optimization, though clinical evidence supporting broad longevity claims remains limited.
NAD+ webinar set to examine delivery dilemma
NAD+ delivery methods—pills, injections, and pens—are receiving increased clinical scrutiny as the molecule transitions from niche longevity therapy to mainstream wellness category. The effectiveness of NAD+ depends less on the molecule itself than on bioavailability, formulation quality, and whether patients maintain consistent use.
Niagen launches telehealth NAD+ injection platform
Niagen Bioscience launched a prescription-only telehealth platform delivering subcutaneous NAD+ injections at home, shifting nicotinamide riboside from over-the-counter supplement to clinician-directed pharmaceutical intervention. The model combines telehealth access with clinical oversight and compounded pharmaceutical-grade dosing, though the clinical evidence supporting NAD+ supplementation for meaningful longevity outcomes remains incomplete.
Engineering longevity with the ZEUGMA hyperbaric chamber
Hyperbaric oxygen therapy, traditionally confined to clinical medicine, is being deployed in performance and longevity settings through chambers like ZEUGMA, which operate at pressures enabling oxygen to dissolve into plasma at concentrations far exceeding atmospheric levels. The mechanism addresses tissue oxygen delivery and cellular repair, though evidence for durable benefits in healthy individuals remains under investigation.
Nuchido announced as Catalyst Partner for The Longevity Show
Nuchido addresses NAD+ decline through targeted restoration of the salvage pathway rather than simple precursor replacement, supported by randomized controlled human trials demonstrating improvements in inflammation, glycation, and biological age markers. This systems-biology approach represents a maturation of the NAD+ intervention landscape toward mechanistic rather than marketing-driven solutions.
EEG Software Maps Cognitive Processing Before Clinical Decline
VoxNeuro received FDA 510(k) clearance for software that analyzes brain electrical activity through standardized cognitive tasks, providing clinicians with quantified measures of neural function against a reference database of nearly 20,000 healthy adult data points. The tool supports assessment of cognitive processing without delivering diagnosis, positioning it as an objective biomarker for brain function relevant to early detection and monitoring.
Niagen Bioscience launches Niagen Plus telehealth platform
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
Designing therapies patients can live with
Light-activated photodynamic therapy for cutaneous T-cell lymphoma demonstrates a treatment design principle critical to chronic disease management: therapies must be engineered for decades of safe, repeatable use rather than optimized solely for efficacy. For conditions that persist across a lifespan, cumulative toxicity and patient burden become as clinically significant as the primary disease.
Psilocybin and human longevity
Psilocybin demonstrates measurable effects on lifespan and healthspan markers in preclinical models, operating through neuroplasticity pathways and stress-response modulation. The compound's capacity to alter consciousness-linked neural signaling raises questions about its role in longevity pathways previously associated with psychological resilience and systemic stress tolerance.
Renue by Science wins precision recovery & performance award
Renue by Science received recognition for its Total NAD+ Restoration Protocol, a multi-pathway supplement approach designed to address age-related NAD+ decline through enhanced precursor delivery, reduced NAD+ catabolism, improved mitochondrial efficiency, and cellular repair support. NAD+ restoration represents a targeted intervention in the metabolic foundation of cellular aging.
New functional brain assessment system rolls out in the US
QuantalX Neuroscience has launched Delphi MD, an FDA-cleared non-invasive system that quantifies real-time functional brain network activity using transcranial magnetic stimulation, electroencephalography, and AI analytics. This technology enables clinicians to detect subtle changes in brain function before structural damage or cognitive decline becomes apparent, shifting neurological care from reactive symptom management to preventive assessment.
Hepatic Thyroid Hormone Decline Drives Aging Liver Disease
Aging and Western diet consumption jointly impair thyroid hormone metabolism in the liver through altered deiodinase enzyme activity, depleting active thyroid hormone at the cellular level and accelerating fatty liver disease progression. Restoring thyroid hormone signaling reverses senescence markers and reduces inflammation, identifying a therapeutic pathway for metabolic liver disease in aging populations.
Osteoboost raises $8m to scale bone wearable
Osteoboost has secured $8 million in funding to scale an FDA-cleared wearable device that delivers calibrated vibration therapy to address osteopenia, a condition affecting 44 million Americans currently managed with minimal intervention. The device represents a regulated approach to early-stage bone loss prevention in a market where pharmacological treatment remains absent and diagnostic management remains largely passive.
Brain-centered longevity: why trauma recovery shapes aging
Jupiter Neurosciences acquired exclusive US rights to ALA-002, a clinical-stage psychedelic therapy for treatment-resistant PTSD and severe anxiety, signaling a strategic shift in longevity medicine toward brain-centered approaches. The deal reflects growing recognition that neurological health and trauma recovery may be foundational to aging biology itself.
Bioelectric Therapy Restores Retinal Function in Dry AMD
i-Lumen Scientific has enrolled the first U.S. patient in i-SIGHT2, a pivotal trial testing bioelectric microcurrent stimulation delivered through the eyelid to restore retinal function in intermediate to advanced dry age-related macular degeneration. The therapy aims to repolarize retinal pigment epithelium cells and improve photoreceptor function, addressing a condition with limited treatment options.
CorTec receives FDA breakthrough device designation
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
AEON Clinic rolls out ExoMind for complex mental health conditions
AEON Clinic has launched ExoMind, an integrated treatment program combining clinical assessment, neuromodulation, and psychotherapy for treatment-resistant mental health conditions including OCD, ADHD, and PTSD. The program lacks published clinical trial data or specified regulatory clearances, positioning it as a personalized approach to conditions poorly managed by standard therapies.
The regulatory path for rescheduling psychedelics for healthspan
Psychedelics show promise for cognitive resilience and neural regeneration, but Schedule I classification creates regulatory barriers that prevent clinical investigation of their healthspan applications. Current drug policy frameworks were designed for acute disease endpoints and cannot adequately evaluate interventions targeting age-related decline over extended timeframes.
I-Lumen receives FDA IDE to start U.S. i-SIGHT2 enrollment
I-Lumen Scientific received FDA approval to expand enrollment of i-SIGHT2, a clinical trial evaluating non-invasive bioelectric stimulation for intermediate to advanced dry age-related macular degeneration. The therapy aims to restore retinal function through microcurrent stimulation of the retinal pigment epithelium, with U.S. enrollment beginning in late April 2026.
NK Cell Therapy Targets Immune Dysfunction in Neurodegeneration
NKGen Biotech is advancing Troculeucel, an autologous natural killer cell therapy, through Phase 2 trials for Alzheimer's disease with expansion into other neurodegenerative conditions. The approach targets immune system dysfunction in neurodegeneration, representing a distinct mechanistic pathway from conventional pharmacological interventions.
Neuroprotective agent targets chemotherapy nerve damage prevention
AnHorn Medicines has initiated a Phase 1 trial of AH-008, a first-in-class neuroprotective agent designed to prevent chemotherapy-induced peripheral neuropathy by targeting neuroinflammatory pathways before irreversible nerve damage occurs. Since 60–70% of chemotherapy patients develop CIPN and one-third experience persistent symptoms beyond six months with no approved preventive options, this intervention addresses a significant clinical gap in cancer supportive care.
Neural microtissue therapy cuts Parkinson's recovery time by 50%
TreeFrog Therapeutics reports that TFG-001, a 3D neural microtissue therapy, achieves dopamine release within 48 hours and accelerates motor recovery in Parkinson's models to approximately 13 weeks—4 to 15 weeks faster than existing cell therapies. The advancement addresses a critical gap in neurodegeneration treatment by improving graft integration and functional reinnervation.
NeuroEM Therapeutics appoints Dr. W. Scott Burgin as Chief Medical Officer
NeuroEM Therapeutics appointed Dr. W. Scott Burgin as Chief Medical Officer to advance its transcranial electromagnetic treatment technology for Alzheimer's disease and cognitive decline. The non-drug approach uses wearable devices to modulate neuronal activity and holds FDA Breakthrough Device designation, positioning it as a potential alternative to pharmaceutical interventions in neurodegeneration.
Dopamine neuron replacement emerges as Parkinson's regenerative therapy
Kenai Therapeutics completed enrollment in its Phase 1b/2a REPLACE trial of RNDP-001, an off-the-shelf cell therapy designed to replace dopamine-producing neurons lost to Parkinson's disease rather than merely compensate for their absence. This approach represents a fundamental shift from symptomatic management toward actual neural regeneration, with potential implications for how neurodegenerative diseases are treated.